Clinical Trials in Saint Charles, Missouri
19 recruiting
Showing 1–19 of 19 trials
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
Social Anxiety Disorder (SAD)
Vanda Pharmaceuticals500 enrolled29 locationsNCT07221578
Recruiting
Phase 3
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Major Depressive Disorder
Neumora Therapeutics, Inc.1,000 enrolled177 locationsNCT06029439
Recruiting
Phase 3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Hoffmann-La Roche2,000 enrolled482 locationsNCT05878769
Recruiting
Phase 3
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Major Depressive Disorder (MDD)
Vanda Pharmaceuticals500 enrolled38 locationsNCT06830044
Recruiting
Phase 2
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
Chronic Obstructive Pulmonary Disease
Verona Pharma plc480 enrolled54 locationsNCT07016412
Recruiting
Phase 3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
SchizophreniaBipolar I Disorder
Alkermes, Inc.220 enrolled47 locationsNCT05303064
Recruiting
Phase 2
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
Treatment Resistant Depression
atai Therapeutics, Inc.142 enrolled42 locationsNCT06524830
Recruiting
Phase 2
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
Social Anxiety Disorder
VistaGen Therapeutics, Inc.60 enrolled9 locationsNCT06809179
Recruiting
Phase 2
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Generalized Anxiety Disorder (GAD)
AbbVie315 enrolled52 locationsNCT06846320
Recruiting
Phase 2
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Major Depressive Disorder
Autobahn Therapeutics, Inc.230 enrolled50 locationsNCT06633016
Recruiting
Phase 2
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
COPD
Uniquity One (UNI)171 enrolled92 locationsNCT06496620
Recruiting
Phase 3
Randomized Withdrawal Study in Patients With Schizophrenia
Schizophrenia
Vanda Pharmaceuticals400 enrolled22 locationsNCT06961968
Recruiting
Phase 3
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Major Depressive Disorder
Xenon Pharmaceuticals Inc.450 enrolled30 locationsNCT07076407
Recruiting
Phase 3
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences200 enrolled10 locationsNCT06911112
Recruiting
Phase 2
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Sirtsei Pharmaceuticals, Inc.456 enrolled50 locationsNCT06254612
Recruiting
Phase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences600 enrolled18 locationsNCT06966401
Recruiting
Phase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
SchizophreniaAutism Spectrum DisorderBipolar Disorder
Intra-Cellular Therapies, Inc.500 enrolled50 locationsNCT06229210
Recruiting
Phase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Bipolar Depression
Intra-Cellular Therapies, Inc.384 enrolled59 locationsNCT06372964
Recruiting
Phase 4
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Major Depressive Disorder
Axsome Therapeutics, Inc.350 enrolled40 locationsNCT06223880